A Complex Molecular Profile in Melanoma: Intratumoral Heterogeneity and Therapeutic Implications
Open Access
- 4 November 2026
- journal article
- case report
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9870
Abstract
Complex molecular alterations in cancers influence tumor biology, therapeutic response, and resistance. We report a case of cutaneous melanoma demonstrating extensive intratumoral heterogeneity with important clinical implications. A 77-year-old man with stage IIA cutaneous melanoma developed an isolated nodal recurrence one year after resection. Comprehensive next-generation sequencing of the metastatic lesion revealed an uncommon genomic profile consisting of a class 3 BRAF Y472V mutation, two NF1 loss-of-function mutations, and two concurrent KIT mutations: a dominant, potentially targetable K642E mutation and a low-frequency D816V mutation associated with resistance to tyrosine kinase inhibitors. The tumor exhibited a high tumor mutational burden and microsatellite stability. The patient received neoadjuvant nivolumab plus relatlimab followed by surgical resection, achieving complete pathologic response. Repeat sequencing of the resected specimen demonstrated complete molecular clearance of all previously detected variants. This case illustrates the value of comprehensive genomic profiling in revealing biologically complex melanoma with coexisting driver and resistance-associated alterations. The presence of a treatment-naïve KIT resistance mutation suggests preexisting subclonal heterogeneity that may influence future targeted therapy, while high tumor mutational burden and NF1 loss may have contributed to the excellent response to immune checkpoint blockade.Keywords
This publication has 28 references indexed in Scilit:
- The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanomaCell Reports, 2025
- BRAF — a tumour-agnostic drug target with lineage-specific dependenciesNature Reviews Clinical Oncology, 2024
- Neoadjuvant relatlimab and nivolumab in resectable melanomaNature, 2022
- Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapyCell Reports, 2022
- NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsEuropean Journal of Cancer, 2021
- Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic DatabasesJAMA Network Open, 2021
- Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RASNature, 2017
- Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomasNature Genetics, 2015
- Genomic Classification of Cutaneous MelanomaCell, 2015
- KIT as a Therapeutic Target in Metastatic MelanomaJAMA, 2011